Posts tagged brain cells
Articles and news from the latest research reports.
UAlberta medical researchers make key discovery in fight against Alzheimer’s disease
Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer’s brain cells.
Jack Jhamandas, a researcher with the Faculty of Medicine & Dentistry at the U of A, is the principal investigator with the team whose research results were recently published in the peer-reviewed publication The Journal of Neuroscience. He works in the Division of Neurology.
The team took brain tissue from animal models with Alzheimer’s disease and tested the tissue in the lab, looking specifically at the cells’ memory capacity. When brain cells are shocked by a barrage of electrical impulses, the cells “remember” the experience and this is a typical way to test or measure memory in the lab setting.
Amyloid protein, which is found in abnormally large amounts in the memory and cognition parts of the brains of Alzheimer’s patients, diminishes memory. A sister protein, known as amylin, which comes from the pancreas of diabetic patients, has the same impact on memory cells.Jhamandas and his team demonstrated last year that a diabetes drug that never made it to market, known as AC253, could block the toxic effects of amyloid protein that lead to brain cell death.
In the lab, Jhamandas and his teammates, which included Ryoichi Kimura, a visiting scientist from Japan, tested the memory of normal brain cells and those with Alzheimer’s—both from animal models. When the drug AC253 was given to brain cells with Alzheimer’s and the shock memory tests were redone, memory was restored to levels similar to those in normal cells.
“This is very important because it tells us that drugs like this might be able to restore memory, even after Alzheimer’s disease may have set in,” says Jhamandas.
Turning urine into brain cells
Chinese researchers have devised a new technique for reprogramming cells from human urine into immature brain cells that can form multiple types of functioning neurons and glial cells. The technique, published in the journal Nature Methods, could prove useful for studying the cellular mechanisms of neurodegenerative conditions such as Alzheimer’s and Parkinson’s and for testing the effects of new drugs that are being developed to treat them.
Stem cells offer the hope of treating these debilitating diseases, but obtaining them from human embryos poses an ethical dilemma. We now know that cells taken from the adult human body can be made to revert to a stem cell-like state and then transformed into virtually any other type of cell. This typically involves using genetically engineered viruses that shuttle control genes into the nucleus and inserts them into the chromosomes, whereupon they activate genes that make them pluripotent, or able to re-differentiate into another type of cell.
In 2008, for example, American researchers took skin cells from an 82-year-old patient with amyotrophic lateral sclerosis and reprogrammed them into motor neurons. Cells obtained in this way could help us gain a better understanding of such diseases. Grafts of patients’ own cells do not elicit an immune response, so this approach may eventually lead to effective cell transplantation therapies. But it also has its problems – it appears that the reprogramming process destabilizes the genome and causes mutations, and that iPSCs may therefore harbour genetic defects that render them useless.
Last year, Duanqing Pei of the Chinese Academy of Sciences and his colleagues reported that human urine contains skin-like cells from the lining of the kidney tubules which can be efficiently reprogrammed, via the pluripotent state, into neurons, glia, liver cells and heart muscle cells. Now they have improved on the approach, making it quicker, more efficient and possibly less prone to errors.
In the new study, they isolated cells from urine samples given by three donors, aged 10, 25 and 37, and converted them directly into neural progenitors. They then grew these cells in Petri dishes and drove them to differentiate into mature neurons that can generate nervous impulses, and also into astrocytes and oligodendrocytes, two types of glial cell found in the human brain. Finally, they transplanted the re-programmed neurons and astrocytes into the brains of newborn rats, and found that the cells had survived when they examined the brains a month later, but it remains to be seen if they can survive for longer, and if they integrate into the existing circuits to be become functional.
This isn’t the first time that one type of cell has been converted into another without going through the pluripotent stage – in 2010, researchers from Stanford converted mouse connective tissue cells directly into neurons. The new technique does have a number of advantages, however.
Instead of using a virus to deliver the reprogramming genes, the researchers used a small circular piece of bacterial DNA which can replicate in the cytoplasm. This not only speeds up the process, but also eliminates the need to integrate the reprogramming genes into the chromosome, which is one potential source of genetic mutation, but it’s still not clear whether these cells contain fewer mutations than those reprogrammed using viruses.
Even so, the technique also makes the procedure of generating iPSCs far easier and non-invasive, as the cells can be obtained from a urine sample instead of a blood sample or biopsy. The next logical step will be to generate neurons from urine samples obtained from patients with Alzheimer’s, Parkinson’s, and other neurodegenerative diseases and to determine the extent to which this new non-viral technique damages the DNA.
(Source: Guardian)
Discovery of pathway leading to depression reveals new drug targets
Scientists have identified the key molecular pathway leading to depression, revealing potential new targets for drug discovery, according to research led by King’s College London’s Institute of Psychiatry. The study, published in Neuropsychopharmacology, reveals for the first time that the ‘Hedgehog pathway’ regulates how stress hormones, usually elevated during depression, reduce the number of brain cells.
Depression affects approximately 1 in 5 people in the UK at some point in their lives. The severity of symptoms can range from feelings of sadness and hopelessness to, in the most severe cases, self-harm or suicide. Treatment for depression involves either medication or talking treatment, or usually a combination of the two.
Recent studies have demonstrated that depression is associated with a reduction in a brain process called ‘neurogenesis’- the ability of the brain to produce new brain cells. However, the pathway responsible for this process has, until now, remained unknown.
In this study, Dr Christoph Anacker from the Centre for the Cellular Basis of Behaviour (CCBB) at King’s Institute of Psychiatry and his team studied human stem cells, which are the source of new cells in the human brain, to investigate the effect of stress hormones on brain cell development. The study was funded by the National Institute for Health Research Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London and the Medical Research Council UK.
Stress hormones, such as cortisol, are generally elevated in stress and depression. The team studied stem cells in a laboratory and found that high concentrations of cortisol damaged these stem cells and reduced the number of newborn brain cells. They discovered that a specific signalling mechanism in the cell, the ‘Hedgehog pathway’, is responsible for this process. Then, using an animal model, the team confirmed that exposure to stress inhibited this pathway in the brain.
Finally, in order to test the findings, the researchers used a compound called purmorphamine, which is known to stimulate the Hedgehog pathway. They found that by using this drug, they were able to reverse the damaging effects of stress hormones, and normalise the production of new brain cells.
Do brain cells need to be connected to have meaning?
The classic theory of the brain is one of connections, in which the brain consists of a network of neurons that interact with each other to allow us to think, see, interpret, and understand the world around us. In this model, called distributed representation, an individual neuron by itself has no inherent meaning, but only contributes to a pattern of neuronal activity that has meaning. For example, a certain pattern of many neurons fires when you think “dog” and another pattern for “cat.”
"The belief in distributed representation theory is that a concept or object is not represented by a single neuron in the brain but by a pattern of activations over a number of neurons," explains Asim Roy, a professor of information systems at Arizona State University, to Medical Xpress . "Thus there is no single neuron in the brain representing a cat or a dog. Proponents of this theory claim that a cat or a dog is represented by its microfeatures such as legs, ears, body, tail, and so on. However, they think that neurons have absolutely no meaning on a stand-alone basis. Therefore, they go further and claim that these microfeatures are at the subsymbolic level, which means that meaning arises only when you consider the pattern of activations as a whole. Therefore, there are no neurons representing legs, ears, body, tail, etc. The representation is at a much lower level."
Roy is among a number of scientists working in the fields of neuroscience and artificial intelligence (AI) who suspect that the brain may not be as connected as distributed representation suggests. The basis of their alternative model, called localist representation, is that a single neuron can represent a dog, a cat, or any other object or concept. These neurons can be considered symbols since they have meaning on a stand-alone basis. However, as Roy explains, this doesn’t necessarily mean only one neuron represents a dog; such “concept cells” are high-level neurons, which fire in response to the firing of an assortment of low-level neurons that represent the legs, ears, body, tail, etc.
"In localist representation, there could be separate neurons for a dog and a cat, and also neurons for legs, ears, body, tail, etc.," he said. "It’s very similar to the model in my paper for word recognition, which is an old model from James McClelland [Chair of the Psychology Department at Stanford University] and [the late pioneering neuroscientist] David Rumelhart. You have low-level neurons that detect letters of the alphabet and then high-level neurons for individual words. So letter neurons and word neurons, they both exist."
The origins of this dispute between localist and distributed representation goes back to the early ’80s, to a dispute between the symbol processing hypothesis of artificial intelligence (AI) and the subsymbolic paradigm of connectionists. In the past 30 years, the debate has only intensified.
Precisely engineering 3-D brain tissues
Borrowing from microfabrication techniques used in the semiconductor industry, MIT and Harvard Medical School (HMS) engineers have developed a simple and inexpensive way to create three-dimensional brain tissues in a lab dish.
The new technique yields tissue constructs that closely mimic the cellular composition of those in the living brain, allowing scientists to study how neurons form connections and to predict how cells from individual patients might respond to different drugs. The work also paves the way for developing bioengineered implants to replace damaged tissue for organ systems, according to the researchers.
"We think that by bringing this kind of control and manipulation into neurobiology, we can investigate many different directions," says Utkan Demirci, an assistant professor in the Harvard-MIT Division of Health Sciences and Technology (HST).
Demirci and Ed Boyden, associate professor of biological engineering and brain and cognitive sciences at MIT’s Media Lab and McGovern Institute, are senior authors of a paper describing the new technique, which appears in the Nov. 27 online edition of the journal Advanced Materials. The paper’s lead author is Umut Gurkan, a postdoc at HST, Harvard Medical School and Brigham and Women’s Hospital.
(Source: eurekalert.org)
Double Duty: Immune System Regulator Found to Protect Brain from Effects of Stroke
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke — and thus the cells’ likelihood of suffering permanent damage.
“We set out to find a small molecule with very specific effects in the brain, one that could be the target of a future stroke treatment,” says Valina Dawson, Ph.D., a professor in the Johns Hopkins University School of Medicine’s Institute for Cell Engineering. “What we found is this molecule involved in immune response, which also acts in complex ways on the brain. This opens up a suite of interesting questions about what microRNA-223 is doing and how, but it also presents a challenge to any therapeutic application.” A report on the discovery is published in the Nov. 13 issue of the Proceedings of the National Academy of Sciences.
RNA is best known as a go-between that shuttles genetic information from DNA and then helps produce proteins based on that information. But, Dawson explains, a decade ago researchers unearthed a completely different class of RNA: small, nimble fragments that regulate protein production. In the case of microRNA, one member of this class, that control comes from the ability to bind to RNA messenger molecules carrying genetic information, and thus prevent them from delivering their messages. “Compared with most ways of shutting genes off, this one is very quick,” Dawson notes.
Reasoning that this quick action, along with other properties, could make microRNAs a good target for therapy development, Dawson and her team searched for microRNAs that regulate brain cells’ response to oxygen deprivation.
To do that, they looked for proteins that increased in number in cells subjected to stress, and then examined how production of these proteins was regulated. For many of them, microRNA-223 played a role, Dawson says.
In most cases, the proteins regulated by microRNA-223 turned out to be involved in detecting and responding to glutamate, a common chemical signal brain cells use to communicate with each other. A stroke or other injury can lead to a dangerous excess of glutamate in the brain, as can a range of diseases, including autism and Alzheimer’s.
Because microRNA-223 is involved in regulating so many different proteins, and because it affects glutamate receptors, which themselves are involved in many different processes, the molecule’s reach turned out to be much broader than expected, says Maged M. Harraz, Ph.D., a research associate at Hopkins who led the study. “Before this experiment, we didn’t appreciate that a single microRNA could regulate so many proteins,” he explains.
This finding suggests that microRNA-223 is unlikely to become a therapeutic target in the near future unless researchers figure out how to avoid unwanted side effects, Dawson says.
(Source: hopkinsmedicine.org)
Scripps Research Institute Team Identifies a Potential Cause of Parkinson’s Disease that May Lead to New Treatment Options
Deciphering what causes the brain cell degeneration of Parkinson’s disease has remained a perplexing challenge for scientists. But a team led by scientists from The Scripps Research Institute (TSRI) has pinpointed a key factor controlling damage to brain cells in a mouse model of Parkinson’s disease. The discovery could lead to new targets for Parkinson’s that may be useful in preventing the actual condition.
The team, led by TSRI neuroscientist Bruno Conti, describes the work in a paper published online ahead of print on November 19, 2012 by the Journal of Immunology.
Parkinson’s disease plagues about one percent of people over 60 years old, as well as some younger patients. The disease is characterized by the loss of dopamine-producing neurons primarily in the substantia nigra pars compacta, a region of the brain regulating movements and coordination.
Among the known causes of Parkinson’s disease are several genes and some toxins. However, the majority of Parkinson’s disease cases remain of unknown origin, leading researchers to believe the disease may result from a combination of genetics and environmental factors.
Neuroinflammation and its mediators have recently been proposed to contribute to neuronal loss in Parkinson’s, but how these factors could preferentially damage dopaminergic neurons has remained unclear until now.
Zooming in on the human brain
A visually compelling tour of the human brain, from anatomy to cells to genes and back.
Neurons made from stem cells drive brain activity after transplantation in laboratory model
Researchers and patients look forward to the day when stem cells might be used to replace dying brain cells in Alzheimer’s disease and other neurodegenerative conditions. Scientists are currently able to make neurons and other brain cells from stem cells, but getting these neurons to properly function when transplanted to the host has proven to be more difficult. Now, researchers at Sanford-Burnham Medical Research Institute have found a way to stimulate stem cell-derived neurons to direct cognitive function after transplantation to an existing neural network. The study was published November 7 in the Journal of Neuroscience.
“We showed for the first time that embryonic stem cells that we’ve programmed to become neurons can integrate into existing brain circuits and fire patterns of electrical activity that are critical for consciousness and neural network activity,” said Stuart A. Lipton, M.D., Ph.D., senior author of the study. Lipton is director of Sanford-Burnham’s Del E. Webb Neuroscience, Aging, and Stem Cell Research Center and a clinical neurologist.
The trick turned out to be light. Lipton and his team—including Juan Piña-Crespo, Ph.D., D.V.M., Maria Talantova, M.D., Ph.D., and other colleagues at Sanford-Burnham and Stanford University—transplanted human stem cell-derived neurons into a rodent hippocampus, the brain’s information-processing center. Then they specifically activated the transplanted neurons with optogenetic stimulation, a relatively new technique that combines light and genetics to precisely control cellular behavior in living tissues or animals.
To determine if the newly transplanted, light-stimulated human neurons were actually working, Lipton and his team measured high-frequency oscillations in existing neurons at a distance from the transplanted ones. They found that the transplanted neurons triggered the existing neurons to fire high-frequency oscillations. Faster neuronal oscillations are usually better—they’re associated with enhanced performance in sensory-motor and cognitive tasks.
To sum it up, the transplanted human neurons not only conducted electrical impulses, they also roused neighboring neuronal networks into firing—at roughly the same rate they would in a normal, functioning hippocampus.
The therapeutic outlook for this technology looks promising. “Based on these results, we might be able to restore brain activity—and thus restore motor and cognitive function—by transplanting easily manipulated neuronal cells derived from embryonic stem cells,” Lipton said.
(Source: beaker.sanfordburnham.org)
A better brain implant: Slim electrode cozies up to single neurons
A thin, flexible electrode developed at the University of Michigan is 10 times smaller than the nearest competition and could make long-term measurements of neural activity practical at last.
This kind of technology could eventually be used to send signals to prosthetic limbs, overcoming inflammation larger electrodes cause that damages both the brain and the electrodes.
The main problem that neurons have with electrodes is that they make terrible neighbors. In addition to being enormous compared to the neurons, they are stiff and tend to rub nearby cells the wrong way. The resident immune cells spot the foreigner and attack, inflaming the brain tissue and blocking communication between the electrode and the cells.
The new electrode developed by the teams of Daryl Kipke, a professor of biomedical engineering, Joerg Lahann, a professor of chemical engineering, and Nicholas Kotov, the Joseph B. and Florence V. Cejka Professor of Engineering, is unobtrusive and even friendly in comparison. It is a thread of highly conductive carbon fiber, coated in plastic to block out signals from other neurons. The conductive gel pad at the end cozies up to soft cell membranes, and that close connection means the signals from brain cells come in much clearer.
"It’s a huge step forward," Kotov said. "This electrode is about seven microns in diameter, or 0.007 millimeters, and its closest competitor is about 25 to 100 microns."